NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
Clinical Trials
21 trialsNCT05755828 2023-03-06
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05744037 2023-02-24
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05385263 2022-05-26
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT05286164 2022-04-15
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT04246359 2022-04-07
RIPPLE
Sun Yat-sen University
Phase 2 Unknown
NCT05312476 2022-04-05
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04948788 2021-09-28
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT05014100 2021-08-27
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
Phase 2 Unknown
NCT03245905 2021-03-16
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL
Sun Yat-sen University
Phase 2 Unknown
NCT03639181 2021-03-03
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
Genor Biopharma Co., Ltd.
Phase 2 Unknown
NCT04163302 2019-11-15
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03929107 2019-04-26
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03569696 2019-04-23
NivoM
Sheba Medical Center
Phase 2 Unknown
NCT03258047 2019-02-15
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03373019 2017-12-14
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fudan University
Phase 2 Unknown
NCT03105596 2017-04-11
Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Peking University
Phase 2 Unknown
NCT02456207 2015-05-28
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Sinocelltech Ltd.
Phase 2 Unknown
NCT00927797 2009-06-25
PERLL
Heidelberg University
Phase 2 Unknown